Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome

Journal of the National Medical Association

Volumn 100, Issue 1, 2008, Pages 64-68

  Gulcelik, Nese Ersoz ^a,c   Aral, Yalcin ^b   Serter, Rustu ^b   Koc, Gonul ^b  

^a ANKARA ONCOLOGY HOSPITAL   (Turkey)

^b Ankara Training Hospital   (Turkey)

^c Ankara Onkoloji Hastanesi   (Turkey)

Author keywords

Cardiovascular; Metabolic syndrome; Obstetrics gynecology

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPOADIPONECTINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 38949198705     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31176-7     Document Type: Article

References (40)

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS) arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84:1897-1899.
2. Aziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-2749.
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-1236.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev. 1997;18(6):774-800.
5. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908-915.
6. Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929-1935.
7. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome (PCOS). J Clin Endocrinol Metab. 2006;91:48-53.
8. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
9. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599.
10. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769.
11. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89:447-452.
12. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, Inflammation, and the Expression of the Metabolic Syndrome in Obese Individuals: the Impact of Rapid Weight Loss through Caloric Restriction. J Clin Endocrinol Metab. 2004;89:2697-2700.
13. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
14. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a Biomarker of the Metabolic Syndrome. Circ J. 2004;68:975-981.
15. Matsushita K, Yatsuya H, Tamakoshi K, et al. Comparison of Circulating Adiponectin and Proinflammatory Markers Regarding Their Association with Metabolic Syndrome in Japanese Men. Arterioscler Thromb Vasc Biol. 2006;26(4):871-876.
16. Mohan V, Deepa R, Pradeepa R, et al. Association of low adiponectin levels with the metabolic syndrome - the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism. 2005;54(4):476-481.
17. Ogawa Y, Kikuchi T, Nagasaki K, et al. Usefulness of Serum Adiponectin Level as a Diagnostic Marker of Metabolic Syndrome in Obese Japanese Children. Hypertens Res. 2005;28:51-57.
18. Salmennimi U, Routsalainen E, Pihlajamaki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110:3842-3848.
19. Ducluzeau PH, Cousin P, Malvoisin E, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:3626-3631.
20. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2005;83(6):1708-1716.
21. Spranger J, Möhlig M, Wegewitz U, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol. 2004;61:738-746.
22. Gulcelik NE, Aral Y, Serter R, et al. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22(9):511-515.
23. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
24. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
25. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assesment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
26. Wilson PW, Kannel WB, Silberhatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.
27. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein. Circulation. 1999;100:2473-2476.
28. Ouchi Y, Kihara S, Arita, et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF kappa B signaling through cAMP-dependent pathway. Circulation. 2000;102:1296-1301.
29. Ouchi Y, Kihara S, Arita Y, et al. Adipocyte derived plasma protein, adiponectin, suppress lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057-1063.
30. Arita Y, Kihara S, Ouchi Y, et al. Adipocyte-derived plasma protein, adiponectin, acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105:2893-2898.
31. Huang K, Chen C, Chuang I, et al. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab. 2003;88:4130-4134.
32. Dullaart RPF, de Vries R, van Toi A, et al. Lower plasma adiponectin is a marker of increased intima-media thickness associated with type 2 diabetes mellitus and with male gender. Eur J Endocrinol. 2007;156(3):387-394.
33. Sieminska L, Marek B, Kos-Kudla B, et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest. 2004;27(6):528-534.
34. Guardini L, McTernan PG, Girola A, et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006;189(2):401-407.
35. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85-89.
36. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86:3815-3819.
37. Maeda N, Takahashi M, Funahashi T, et al. PPAR gamma ligands increased expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-2099.
38. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76-81.
39. Nagasaka S, Taniguchi A, Aiso Y, et al. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care. 2003;26:2215-2216.
40. Majuri A, Santaniemi M, Rautio K, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007;156(2):263-269.